CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease
An investigational Cas12a-edited stem cell treatment sharply boosted HbF and largely eliminated vaso-occlusive crises in an early trial
Clinical Scorecard: CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease
At a Glance
Category Detail
Condition Sickle Cell Disease Key Mechanisms CRISPR-Cas12a gene editing targeting HBG1 and HBG2 promoters to reactivate fetal hemoglobin production. Target Population Patients with severe sickle cell disease. Care Setting Clinical trial setting.
Key Highlights
Total hemoglobin increased from 9.8 g/dL to 13.8 g/dL in six months. Fetal hemoglobin levels rose from 2.5% to 48.1%. 27 out of 28 patients had no severe vaso-occlusive events post-infusion. F-cell levels exceeded 99% by month 6. Robust engraftment with neutrophil recovery at 23 days and platelet recovery at 25 days. Guideline-Based Recommendations
Diagnosis
Diagnosis of sickle cell disease confirmed through hemoglobin electrophoresis. Management
Consider CRISPR-Cas12a therapy for eligible patients with severe sickle cell disease. Monitoring & Follow-up
Monitor hemoglobin levels and fetal hemoglobin percentage post-treatment. Risks
Potential risks include febrile neutropenia, stomatitis, and mucosal inflammation. Patient & Prescribing Data
Patients with severe sickle cell disease undergoing gene editing therapy.
CRISPR therapy shows potential for a functional cure without rejection issues associated with traditional bone marrow transplants.
Clinical Best Practices
Utilize CRISPR-Cas12a for targeted gene editing in appropriate patient populations. Ensure comprehensive monitoring of hematologic recovery post-treatment. Educate patients on potential side effects and the nature of the treatment. Related Resources & Content
